Document is current
Any future updates will be listed below
-
Authors
Wu, Lan
Seung, Edward
Xu, Ling
Rao, Ercole
Lord, Dana M.
Wei, Ronnie R. http://orcid.org/0000-0003-3606-6055
Cortez-Retamozo, Virna
Ospina, Beatriz
Posternak, Valeriya
Ulinski, Gregory
Piepenhagen, Peter
Francesconi, Elisa
El-Murr, Nizar http://orcid.org/0000-0001-7793-9436
Beil, Christian
Kirby, Patrick
Li, Aiqun
Fretland, Jennifer
Vicente, Rita
Deng, Gejing
Dabdoubi, Tarik
Cameron, Beatrice
Bertrand, Thomas http://orcid.org/0000-0002-9188-6673
Ferrari, Paul
Pouzieux, Stéphanie
Lemoine, Cendrine
Prades, Catherine
Park, Anna
Qiu, Huawei
Song, Zhili
Zhang, Bailin
Sun, Fangxian
Chiron, Marielle
Rao, Srinivas
Radošević, Katarina http://orcid.org/0000-0002-6769-8402
Yang, Zhi-yong http://orcid.org/0000-0002-9938-5929
Nabel, Gary J. http://orcid.org/0000-0003-0619-4419
- License Information
-
More Information
Article History
Received: 24 July 2019
Accepted: 23 October 2019
First Online: 18 November 2019
Competing interests
: All authors are or were employees of Sanofi while engaged in this research project. Sanofi develops and manufactures cancer treatment medicines. G.J.N. is the Chief Scientific Officer of Sanofi. G.J.N., Z.-y.Y., R.R.W., L.X., E.S., L.W., T.D., B.C., C.L. and C.P. are listed on intellectual property (WO2019074973A2) developed and owned by Sanofi related to the development of novel cancer treatments.
